ticker,event_date,window_start,window_end,symbol,symbols,publishedDate,publishedDateET,date_et,title,text,site,url,image
JNJ,2025-04-15,2025-04-01,2025-04-29,JNJ,,2025-04-01 17:31:00,2025-04-01T17:31:00-04:00,2025-04-01,S&P 500 Gains and Losses Today: Johnson & Johnson Drops as Judge Rejects Liability Settlement,Major U.S. equities indexes finished the first trading day of the second quarter mixed.,investopedia.com,https://www.investopedia.com/s-and-p-500-gains-and-losses-today-tesla-elon-musk-vistra-trade-trump-11707056,https://images.financialmodelingprep.com/news/sp-500-gains-and-losses-today-johnson-johnson-drops-20250401.jpg
JNJ,2025-04-15,2025-04-01,2025-04-29,JNJ,,2025-04-01 16:06:00,2025-04-01T16:06:00-04:00,2025-04-01,Johnson & Johnson Announces Expected Closing Date for Intra-Cellular Acquisition,"NEW BRUNSWICK, N.J.--(BUSINESS WIRE)--Johnson & Johnson (NYSE: JNJ) today announced that following the approval of its pending acquisition of Intra-Cellular Therapies, Inc. by Intra-Cellular Therapies' shareholders on March 27, 2025, Johnson & Johnson intends to complete its acquisition of Intra-Cellular Therapies on or around April 2, 2025. The transaction is expected to accelerate 2025 sales growth for Johnson & Johnson by approximately 0.8% with approximately $0.7 billion in incr.",businesswire.com,https://www.businesswire.com/news/home/20250401997629/en/Johnson-Johnson-Announces-Expected-Closing-Date-for-Intra-Cellular-Acquisition/,https://images.financialmodelingprep.com/news/johnson-johnson-announces-expected-closing-date-for-intracellular-acquisition-20250401.jpg
JNJ,2025-04-15,2025-04-01,2025-04-29,JNJ,,2025-04-01 14:38:12,2025-04-01T14:38:12-04:00,2025-04-01,Why Johnson & Johnson Stock Is Sinking Today,Shares of Johnson & Johnson (JNJ -6.57%) are tumbling on Tuesday. The company's stock lost 6.3% as of 2:25 p.m.,fool.com,https://www.fool.com/investing/2025/04/01/why-johnson-johnson-stock-is-sinking-today/,https://images.financialmodelingprep.com/news/why-johnson-johnson-stock-is-sinking-today-20250401.jpg
JNJ,2025-04-15,2025-04-01,2025-04-29,JNJ,,2025-04-01 13:08:30,2025-04-01T13:08:30-04:00,2025-04-01,"S&P, Nasdaq rise as investors await US tariff clarity; Johnson & Johnson slips, PVV Corp jumps","The S&P 500 experienced volatility on Tuesday and was in the green. Investors were awaiting clarity from US President Donald Trump regarding tariff policy, and weaker-than-expected economic data also put pressure on Wall Street.",invezz.com,https://invezz.com/news/2025/04/01/sp-nasdaq-rise-as-investors-await-us-tariff-clarity-johnson-johnson-slips-pvv-corp-jumps/,https://images.financialmodelingprep.com/news/sp-nasdaq-rise-as-investors-await-us-tariff-clarity-johnson-20250401.jpg
JNJ,2025-04-15,2025-04-01,2025-04-29,JNJ,,2025-04-01 12:05:47,2025-04-01T12:05:47-04:00,2025-04-01,Dogs Of The Dow Chase April's 'Safer' Buy,"Verizon is the only Dow Dog currently meeting the ideal of annual dividends from $1K invested exceeding its single share price. Analysts forecast net gains of 13.06% to 37.60% for the top-ten Dow Dogs by April 2026, with NVIDIA leading. The five lowest-priced Dow Dogs are expected to deliver 39.38% more gain than the general top ten by March 2026.",seekingalpha.com,https://seekingalpha.com/article/4772265-dogs-of-the-dow-chase-april-safer-buy,https://images.financialmodelingprep.com/news/dogs-of-the-dow-chase-aprils-safer-buy-20250401.jpg
JNJ,2025-04-15,2025-04-01,2025-04-29,JNJ,,2025-04-01 11:24:58,2025-04-01T11:24:58-04:00,2025-04-01,Johnson & Johnson shares fall as US judge rejects $10B talc settlement plan,"Johnson & Johnson (NYSE:JNJ) shares moved almost 5% lower after a US bankruptcy judge rejected its $10 billion settlement proposal which sought to resolve tens of thousands of lawsuits alleging its talc-based products caused ovarian cancer. Judge Christopher Lopez of the US Bankruptcy Court for the Southern District of Texas, Houston, dismissed the bankruptcy claim filed by J&J subsidiary Red River Talc, citing flaws in the voting process for personal injury claimants.",proactiveinvestors.com,https://www.proactiveinvestors.com/companies/news/1068923,https://images.financialmodelingprep.com/news/johnson-johnson-shares-fall-as-us-judge-rejects-10b-20250401.jpg
JNJ,2025-04-15,2025-04-01,2025-04-29,JNJ,,2025-04-01 10:47:56,2025-04-01T10:47:56-04:00,2025-04-01,Judge rejects Johnson & Johnson's $10B settlement to end baby powder lawsuits,A judge rejected Johnson & Johnson's $10 billion proposal to end tens of thousands of lawsuits alleging that its products caused ovarian cancer.,nypost.com,https://nypost.com/2025/04/01/business/judge-rejects-johnson-amp-johnsons-10b-settlement-to-end-baby-powder-lawsuits/,https://images.financialmodelingprep.com/news/judge-rejects-johnson-johnsons-10b-settlement-to-end-baby-20250401.jpg
JNJ,2025-04-15,2025-04-01,2025-04-29,JNJ,,2025-04-01 10:30:43,2025-04-01T10:30:43-04:00,2025-04-01,J&J's Third Bankruptcy Attempt to End Talc Suits Rejected,J&J fails in its third attempt to settle tens of thousands of lawsuits claiming its talc-based powder caused cancer.,zacks.com,https://www.zacks.com/stock/news/2438069/j-j-s-third-bankruptcy-attempt-to-end-talc-suits-rejected?cid=CS-STOCKNEWSAPI-FT-analyst_blog|company_news_medical_sector-2438069,https://images.financialmodelingprep.com/news/jjs-third-bankruptcy-attempt-to-end-talc-suits-rejected-20250401.jpg
JNJ,2025-04-15,2025-04-01,2025-04-29,JNJ,,2025-04-01 10:18:19,2025-04-01T10:18:19-04:00,2025-04-01,J&J Dives After Judge Tosses Out $10 Billion Talc-Based Bankruptcy Plan,Johnson & Johnson stock slumped Tuesday after a judge rejected its $10 billion proposal to settle thousands of talc-tied lawsuits. The post J&J Dives After Judge Tosses Out $10 Billion Talc-Based Bankruptcy Plan appeared first on Investor's Business Daily.,investors.com,https://www.investors.com/news/technology/johnson-johnson-stock-bankruptcy-talc-lawsuits/,https://images.financialmodelingprep.com/news/jj-dives-after-judge-tosses-out-10-billion-talcbased-20250401.jpg
JNJ,2025-04-15,2025-04-01,2025-04-29,JNJ,,2025-04-01 09:29:00,2025-04-01T09:29:00-04:00,2025-04-01,"Federal Judge Rejects Johnson & Johnson Bankruptcy Strategy, Paving Way for Talc Victims to Seek Justice in Trial Courts","HOUSTON--(BUSINESS WIRE)--In a resounding victory for thousands of women who have suffered from ovarian cancer linked to Johnson & Johnson's (NYSE:JNJ) talcum powder products, U.S. Bankruptcy Court Judge Christopher Lopez has rejected the company's third attempt to shield itself from liability through bankruptcy. The ruling clears the way for claimants to seek speedy jury trials in state courts and through the bellwether process in multidistrict litigation (MDL). “This decision affirms what.",businesswire.com,https://www.businesswire.com/news/home/20250401705697/en/Federal-Judge-Rejects-Johnson-Johnson-Bankruptcy-Strategy-Paving-Way-for-Talc-Victims-to-Seek-Justice-in-Trial-Courts/,https://images.financialmodelingprep.com/news/federal-judge-rejects-johnson-johnson-bankruptcy-strategy-paving-way-20250401.jpg
JNJ,2025-04-15,2025-04-01,2025-04-29,JNJ,,2025-04-01 08:15:00,2025-04-01T08:15:00-04:00,2025-04-01,Johnson & Johnson Latest Talc Resolution Rejected. The Stock Is Falling.,A bankruptcy judge in Texas rejected a proposal that would have ended most lawsuits saying the products cause ovarian cancer.,barrons.com,https://www.barrons.com/articles/johnson-and-johnson-stock-jnj-talc-bankruptcy-8f3538b8,https://images.financialmodelingprep.com/news/johnson-johnson-latest-talc-resolution-rejected-the-stock-is-falling-20250401.jpg
JNJ,2025-04-15,2025-04-01,2025-04-29,JNJ,,2025-04-01 07:11:19,2025-04-01T07:11:19-04:00,2025-04-01,J&J shares fall after judge rejects $10 billion talc settlement,Johnson & Johnson shares fell more than 3% on Tuesday after a U.S. bankruptcy judge rejected its $10 billion proposal to end tens of thousands of lawsuits alleging that its baby powder and other talc products cause ovarian cancer.,reuters.com,https://www.reuters.com/business/healthcare-pharmaceuticals/jj-shares-fall-after-judge-rejects-10-billion-talc-settlement-2025-04-01/,https://images.financialmodelingprep.com/news/jj-shares-fall-after-judge-rejects-10-billion-talc-20250401.jpg
JNJ,2025-04-15,2025-04-01,2025-04-29,JNJ,,2025-04-02 18:50:47,2025-04-02T18:50:47-04:00,2025-04-02,Johnson & Johnson (JNJ) Exceeds Market Returns: Some Facts to Consider,"The latest trading day saw Johnson & Johnson (JNJ) settling at $155.36, representing a +1.38% change from its previous close.",zacks.com,https://www.zacks.com/stock/news/2439353/johnson-johnson-jnj-exceeds-market-returns-some-facts-to-consider?cid=CS-STOCKNEWSAPI-FT-tale_of_the_tape|yseop_template_6-2439353,https://images.financialmodelingprep.com/news/johnson-johnson-jnj-exceeds-market-returns-some-facts-to-20250402.jpg
JNJ,2025-04-15,2025-04-01,2025-04-29,JNJ,,2025-04-02 18:15:00,2025-04-02T18:15:00-04:00,2025-04-02,Worried About the Economy? 2 No-Brainer Buys to Shield Your Portfolio.,"The Nasdaq Composite (^IXIC 0.87%) and the S&P 500 (^GSPC 0.67%) sank, shifting in and out of correction territory in the first quarter of the year for one big reason: investors have been worried about the economy. President Donald Trump is putting tariffs on imports, and economists predict this could lead to higher inflation and a slowdown in growth.",fool.com,https://www.fool.com/investing/2025/04/02/worried-about-the-economy-2-no-brainer-buys/,https://images.financialmodelingprep.com/news/worried-about-the-economy-2-nobrainer-buys-to-shield-20250402.jpg
JNJ,2025-04-15,2025-04-01,2025-04-29,JNJ,,2025-04-02 16:15:00,2025-04-02T16:15:00-04:00,2025-04-02,NANOBIOTIX Provides Business Update and Reports Full Year 2024 Financial Results,"Global development program for JNJ-1900 (NBTXR3) proceeding as planned, with opportunity to address one of the largest untapped markets in oncology through lead programs in head and neck cancer and lung cancer Disciplined financial strategy toward long-term sustainability and growth continues to strengthen financial position through focused allocation of capital, the receipt of a planned milestone payment, the transfer of sponsorship for NANORAY-312, and an amendment to the global licensing agreement for JNJ-1900 (NBTXR3) Curadigm, a next generation nanotherapeutic platform designed to reshape drug design and development across multiple therapeutic classes and disease areas, has launched Cash runway extended into mid-2026 and reduction of operational cash burn expected beyond mid-2026 with €49.7 million in cash and cash equivalents as of December 31, 2024 Clinical data readouts in 2025 from Phase 1 and 2 studies in RM-HNSCC, pancreatic cancer, NSCLC amenable to re-irradiation, melanoma and esophageal cancer Conference call and webcast scheduled for April 3, 2025 at 8:00 A.M. EDT / 2:00 P.M.",globenewswire.com,https://www.globenewswire.com/news-release/2025/04/02/3054710/0/en/NANOBIOTIX-Provides-Business-Update-and-Reports-Full-Year-2024-Financial-Results.html,https://images.financialmodelingprep.com/news/nanobiotix-provides-business-update-and-reports-full-year-2024-financial-20250402.jpg
JNJ,2025-04-15,2025-04-01,2025-04-29,JNJ,,2025-04-02 12:26:56,2025-04-02T12:26:56-04:00,2025-04-02,Stock Of The Day: Will Johnson & Johnson Rally? The Sell-Off May Have Ended,"Shares of Johnson & Johnson  JNJ are trading higher on Wednesday. Yesterday, they were down more than 7.5%.",benzinga.com,https://www.benzinga.com/trading-ideas/technicals/25/04/44610672/stock-of-the-day-will-johnson-johnson-rally-the-sell-off-may-have-ended,https://images.financialmodelingprep.com/news/stock-of-the-day-will-johnson-johnson-rally-the-20250402.jpg
JNJ,2025-04-15,2025-04-01,2025-04-29,JNJ,,2025-04-02 09:55:56,2025-04-02T09:55:56-04:00,2025-04-02,Why Investors Need to Take Advantage of These 2 Medical Stocks Now,Investors looking for ways to find stocks that are set to beat quarterly earnings estimates should check out the Zacks Earnings ESP.,zacks.com,https://www.zacks.com/stock/news/2438804/why-investors-need-to-take-advantage-of-these-2-medical-stocks-now?cid=CS-STOCKNEWSAPI-FT-tale_of_the_tape|zacks_education_earnings_esp-2438804,https://images.financialmodelingprep.com/news/why-investors-need-to-take-advantage-of-these-2-20250402.jpg
JNJ,2025-04-15,2025-04-01,2025-04-29,JNJ,,2025-04-02 08:44:00,2025-04-02T08:44:00-04:00,2025-04-02,"Johnson & Johnson Closes Landmark Intra-Cellular Therapies, Inc. Acquisition to Solidify Neuroscience Leadership","NEW BRUNSWICK, N.J.--(BUSINESS WIRE)--Johnson & Johnson (NYSE: JNJ) today announced it has completed its acquisition of Intra-Cellular Therapies, Inc. Intra-Cellular Therapies is now part of Johnson & Johnson and will operate as a business unit within Johnson & Johnson Innovative Medicine. “At Johnson & Johnson, we are committed to transforming care for the millions of people worldwide living with neuropsychiatric and neurodegenerative disorders,” said Joaquin Duato, Chairman an.",businesswire.com,https://www.businesswire.com/news/home/20250402861736/en/Johnson-Johnson-Closes-Landmark-Intra-Cellular-Therapies-Inc.-Acquisition-to-Solidify-Neuroscience-Leadership/,https://images.financialmodelingprep.com/news/johnson-johnson-closes-landmark-intracellular-therapies-inc-acquisition-to-20250402.jpg
JNJ,2025-04-15,2025-04-01,2025-04-29,JNJ,,2025-04-02 07:30:00,2025-04-02T07:30:00-04:00,2025-04-02,3 Wide-Moat Dividend Stars For A Championship Portfolio,"I linked investing to baseball, showing how consistency, like the A's Moneyball approach, wins long term. Steady dividend growers and low-volatility stocks outperform, especially in rocky markets. Top teams like the Dodgers now pair consistency with big spending. Similarly, investors need financially strong, wide-moat stocks with rising cash flow, durable dividends, and resilience. Moreover, I'm targeting stocks with these traits: reliable growth, low payout ratios, and recession-proof models. Like championship teams, they're built to win over time.",seekingalpha.com,https://seekingalpha.com/article/4772232-3-wide-moat-dividend-stars-for-championship-portfolio,https://images.financialmodelingprep.com/news/3-widemoat-dividend-stars-for-a-championship-portfolio-20250402.jpg
JNJ,2025-04-15,2025-04-01,2025-04-29,JNJ,,2025-04-03 11:00:36,2025-04-03T11:00:36-04:00,2025-04-03,JNJ vs. PFE: Which Drug Giant is a Better Buy Now?,Both JNJ & PFE expect their sales and profits to improve in 2025.,zacks.com,https://www.zacks.com/stock/news/2439812/jnj-vs-pfe-which-drug-giant-is-a-better-buy-now?cid=CS-STOCKNEWSAPI-FT-analyst_blog|most_popular_stocks-2439812,https://images.financialmodelingprep.com/news/jnj-vs-pfe-which-drug-giant-is-a-better-20250403.jpg
JNJ,2025-04-15,2025-04-01,2025-04-29,JNJ,,2025-04-04 16:44:12,2025-04-04T16:44:12-04:00,2025-04-04,4 Blue Chip Pharmaceutical High-Yield Dividend Stocks Are Tariff Winners,"With some pharmaceutical stocks paying 4% and higher dividends, they may be the perfect total return idea for the rest of 2025.",247wallst.com,https://247wallst.com/investing/2025/04/04/4-blue-chip-pharmaceutical-high-yield-dividend-stocks-are-tariff-winners/,https://images.financialmodelingprep.com/news/4-blue-chip-pharmaceutical-highyield-dividend-stocks-are-tariff-20250404.jpg
JNJ,2025-04-15,2025-04-01,2025-04-29,JNJ,,2025-04-04 13:01:12,2025-04-04T13:01:12-04:00,2025-04-04,"1 Ideal Buy From 23 ""Safer"" April Dividend Dogs In 50 Fortune World's Most Admired Companies (FWMAC)","1 Ideal Buy From 23 ""Safer"" April Dividend Dogs In 50 Fortune World's Most Admired Companies (FWMAC)",seekingalpha.com,https://seekingalpha.com/article/4773059-1-ideal-buy-from-23-safer-april-dividend-dogs-in-50-fortune-worlds-most-admired-companies-fwmac,https://images.financialmodelingprep.com/news/1-ideal-buy-from-23-safer-april-dividend-dogs-20250404.jpg
JNJ,2025-04-15,2025-04-01,2025-04-29,JNJ,,2025-04-04 08:05:00,2025-04-04T08:05:00-04:00,2025-04-04,TREMFYA® (guselkumab) is the first and only IL-23 inhibitor to significantly reduce both the signs and symptoms and the progression of structural damage in adults living with active psoriatic arthritis,"TREMFYA® demonstrated clinically meaningful and statistically significant efficacy in patients with active psoriatic arthritis at risk for structural damage in Phase 3b study Topline results demonstrate efficacy across multiple domains at Week 24, reinforcing TREMFYA® as a first-line treatment option for patients with active psoriatic arthritis SPRING HOUSE, Pa. , April 4, 2025 /PRNewswire/ -- Johnson & Johnson (NYSE: JNJ) today announced that the TREMFYA® (guselkumab) Phase 3b APEX study achieved both its primary endpoint (ACR20a) of reducing signs and symptoms and its major secondary endpoint of reducing progression of structural damage as measured by radiographic progression at 24 weeks, in adults living with active psoriatic arthritis (PsA), compared to placebo.1 TREMFYA® is the first and only fully-human, dual-acting monoclonal antibody approved to treat PsA that blocks IL-23 while also binding to CD64, a receptor on cells that produce IL-23.",prnewswire.com,https://www.prnewswire.com/news-releases/tremfya-guselkumab-is-the-first-and-only-il-23-inhibitor-to-significantly-reduce-both-the-signs-and-symptoms-and-the-progression-of-structural-damage-in-adults-living-with-active-psoriatic-arthritis-302420476.html,https://images.financialmodelingprep.com/news/tremfya-guselkumab-is-the-first-and-only-il23-inhibitor-20250404.jpg
JNJ,2025-04-15,2025-04-01,2025-04-29,JNJ,,2025-04-05 08:00:00,2025-04-05T08:00:00-04:00,2025-04-05,"5 Relatively Secure And Cheap Dividend Stocks, Yields Up To 8% (April 2025)","This article is part of our monthly series where we highlight five large-cap, relatively safe, dividend-paying companies offering significant discounts to their historical norms. The market is volatile with economic uncertainties, but investing consistently in solid dividend-paying stocks with reasonable valuations is a good idea. We go over our filtering process to select just five conservative DGI stocks from more than 7,500 companies that are traded on U.S. exchanges, including OTC networks.",seekingalpha.com,https://seekingalpha.com/article/4772468-5-relatively-secure-cheap-dividend-stocks-yields-8-percent-april-2025,https://images.financialmodelingprep.com/news/5-relatively-secure-and-cheap-dividend-stocks-yields-up-20250405.jpg
JNJ,2025-04-15,2025-04-01,2025-04-29,JNJ,,2025-04-05 07:15:39,2025-04-05T07:15:39-04:00,2025-04-05,4 of Wall Street's Most Beloved Blue-Chip Dividend Stocks Are Sale-Priced April Bargains,Large-capitalization blue-chip dividend stocks are a favorite among investors for a good reason.,247wallst.com,https://247wallst.com/investing/2025/04/05/4-of-wall-streets-most-beloved-blue-chip-dividend-stocks-are-sale-priced-march-bargains/,https://images.financialmodelingprep.com/news/4-of-wall-streets-most-beloved-bluechip-dividend-stocks-20250405.jpg
JNJ,2025-04-15,2025-04-01,2025-04-29,JNJ,,2025-04-07 16:25:00,2025-04-07T16:25:00-04:00,2025-04-07,Johnson & Johnson to Participate in the BofA Securities 2025 Healthcare Conference,"NEW BRUNSWICK, N.J.--(BUSINESS WIRE)--Johnson & Johnson (NYSE: JNJ) will present at the BofA Securities 2025 Healthcare Conference on Tuesday, May 13th, 2025. Management will participate in a Fireside Chat at 1:40 p.m. Eastern Time. A live audio webcast of the presentation will be accessible through Johnson & Johnson's Investor Relations website at www.investor.jnj.com. An archived edition of the session will be available later that day. The audio webcast replay will be available approx.",businesswire.com,https://www.businesswire.com/news/home/20250407500165/en/Johnson-Johnson-to-Participate-in-the-BofA-Securities-2025-Healthcare-Conference/,https://images.financialmodelingprep.com/news/johnson-johnson-to-participate-in-the-bofa-securities-2025-20250407.jpg
JNJ,2025-04-15,2025-04-01,2025-04-29,JNJ,,2025-04-07 09:40:44,2025-04-07T09:40:44-04:00,2025-04-07,Big Pharma Stocks Dive Amid Trade War Jitters & Inflation Woes,"Shares of pharma giants like PFE, J&J, AZN, MRK and ABBV decline on investor concerns that retaliatory tariffs could drive up drug prices for U.S. consumers.",zacks.com,https://www.zacks.com/stock/news/2441145/big-pharma-stocks-dive-amid-trade-war-jitters-inflation-woes?cid=CS-STOCKNEWSAPI-FT-analyst_blog|industry_focus-2441145,https://images.financialmodelingprep.com/news/big-pharma-stocks-dive-amid-trade-war-jitters-inflation-20250407.jpg
JNJ,2025-04-15,2025-04-01,2025-04-29,JNJ,,2025-04-07 05:32:00,2025-04-07T05:32:00-04:00,2025-04-07,"European Commission approves Johnson & Johnson's subcutaneous DARZALEX® (daratumumab)-based quadruplet regimen for the treatment of patients with newly diagnosed multiple myeloma, regardless of transplant eligibility",Approval cements daratumumab as a foundational therapy in newly diagnosed multiple myeloma and the only anti-CD38 antibody for all patient types in this setting,globenewswire.com,https://www.globenewswire.com/news-release/2025/04/07/3056498/0/en/European-Commission-approves-Johnson-Johnson-s-subcutaneous-DARZALEX-daratumumab-based-quadruplet-regimen-for-the-treatment-of-patients-with-newly-diagnosed-multiple-myeloma-regard.html,https://images.financialmodelingprep.com/news/european-commission-approves-johnson-johnsons-subcutaneous-darzalex-daratumumabbased-quadruplet-20250407.jpg
JNJ,2025-04-15,2025-04-01,2025-04-29,JNJ,,2025-04-08 10:19:24,2025-04-08T10:19:24-04:00,2025-04-08,Cramer's Stop Trading: Johnson & Johnson,Jim Cramer breaks down why he's keeping an eye on shares of Johnson & Johnson.,youtube.com,https://www.youtube.com/watch?v=wiHPGIs16p8,https://images.financialmodelingprep.com/news/cramers-stop-trading-johnson-johnson-20250408.jpg
JNJ,2025-04-15,2025-04-01,2025-04-29,JNJ,,2025-04-08 05:38:00,2025-04-08T05:38:00-04:00,2025-04-08,"Johnson & Johnson highlights new data, demonstrating long-term sustained disease control in adults living with generalised myasthenia gravis (gMG)",New compelling results demonstrate 18 months of both sustained reduction in immunoglobulin G antibodies and sustained improvement in gMG symptoms in pivotal Vivacity-MG3 study and open label extension phase,globenewswire.com,https://www.globenewswire.com/news-release/2025/04/08/3057399/0/en/Johnson-Johnson-highlights-new-data-demonstrating-long-term-sustained-disease-control-in-adults-living-with-generalised-myasthenia-gravis-gMG.html,https://images.financialmodelingprep.com/news/johnson-johnson-highlights-new-data-demonstrating-longterm-sustained-disease-control-20250408.jpg
JNJ,2025-04-15,2025-04-01,2025-04-29,JNJ,,2025-04-08 03:30:00,2025-04-08T03:30:00-04:00,2025-04-08,"Johnson & Johnson highlights new data, demonstrating long-term sustained disease control in adults living with generalised myasthenia gravis (gMG)",New compelling results demonstrate 18 months of both sustained reduction in immunoglobulin G antibodies and sustained improvement in gMG symptoms in pivotal Vivacity-MG3 study and open label extension phase,globenewswire.com,https://www.globenewswire.com/news-release/2025/04/08/3057337/0/en/Johnson-Johnson-highlights-new-data-demonstrating-long-term-sustained-disease-control-in-adults-living-with-generalised-myasthenia-gravis-gMG.html,https://images.financialmodelingprep.com/news/johnson-johnson-highlights-new-data-demonstrating-longterm-sustained-disease-20250408.jpg
JNJ,2025-04-15,2025-04-01,2025-04-29,JNJ,,2025-04-08 03:00:00,2025-04-08T03:00:00-04:00,2025-04-08,"Johnson & Johnson highlights new data that showcase the strength of nipocalimab, demonstrating long-term sustained disease control in adults living with generalized myasthenia gravis (gMG)","New compelling results demonstrate 18 months of both sustained reduction in immunoglobulin G antibodies and sustained improvement in gMG symptoms in pivotal Vivacity-MG3 study and open-label extension phase Up to 128 weeks and 180 patient years of follow-up in the open-label extensiona confirm a safety profile consistent with the Phase 3 Vivacity-MG3 study  45% of the patients receiving steroids at open-label extension baseline were able to decrease or discontinue their steroid use  Additionally, the nipocalimab plus standard of care (SOC) group demonstrated four times greater odds of improving and maintaining the strength and function of different muscle groups as measured by QMG b  response versus placebo plus SOC in the 24-week double blind phase of the study  SPRING HOUSE, Pa. , April 8, 2025 /PRNewswire/ -- Johnson & Johnson (NYSE: JNJ) today announced results from additional analyses of the Phase 3 Vivacity-MG3 double-blind study and the ongoing open-label extensiona (OLE), evaluating the long-term efficacy and safety of investigational nipocalimab in a broad population of antibody-positive (anti-AChR+, anti-MuSK+, anti-LRP4+) adults with generalized myasthenia gravis (gMG).1 ,2 Patients treated with nipocalimab plus standard of care (SOC) maintained improvements in their MG-ADLc and QMGb scores over 84 weeks with sustained reductions in total immunoglobulin G (IgG).1 These data are included in a presentation (Session 7 #022) and are among 12 abstracts that Johnson & Johnson will present at the American Academy of Neurology (AAN) 2025 Meeting in San Diego, California, which includes an oral presentation on QMG score improvements from the double-blind phase of the Phase 3 Vivacity-MG3 study.",prnewswire.com,https://www.prnewswire.com/news-releases/johnson--johnson-highlights-new-data-that-showcase-the-strength-of-nipocalimab-demonstrating-long-term-sustained-disease-control-in-adults-living-with-generalized-myasthenia-gravis-gmg-302422509.html,https://images.financialmodelingprep.com/news/johnson-johnson-highlights-new-data-that-showcase-the-strength-20250408.jpg
JNJ,2025-04-15,2025-04-01,2025-04-29,JNJ,,2025-04-09 18:32:25,2025-04-09T18:32:25-04:00,2025-04-09,BMO's Siegerman talks the impact of tariffs on pharmaceutical stocks,"Evan Seigerman, BMO, joins 'Fast Money' to talk the impact of tariffs on pharma space.",youtube.com,https://www.youtube.com/watch?v=xdiZR32aDN0,https://images.financialmodelingprep.com/news/bmos-siegerman-talks-the-impact-of-tariffs-on-pharmaceutical-20250409.jpg
JNJ,2025-04-15,2025-04-01,2025-04-29,JNJ,,2025-04-09 15:59:57,2025-04-09T15:59:57-04:00,2025-04-09,Trump's Tariffs Circle Pharma Industry: Who It Affects And How It May Play Out,"The Trump administration's proposed tariffs on pharmaceuticals have caused significant market turmoil today, with major Pharma stocks plummeting globally. Despite pledges to increase U.S. manufacturing, companies like Eli Lilly and Novo Nordisk are suffering substantial share price declines. The feasibility of relocating drug manufacturing to the U.S. is highly questionable, potentially leading to drug shortages and higher domestic prices.",seekingalpha.com,https://seekingalpha.com/article/4774073-trump-tariffs-circle-pharma-industry-who-it-affects-how-it-may-play-out,https://images.financialmodelingprep.com/news/trumps-tariffs-circle-pharma-industry-who-it-affects-and-20250409.jpg
JNJ,2025-04-15,2025-04-01,2025-04-29,JNJ,,2025-04-09 14:27:39,2025-04-09T14:27:39-04:00,2025-04-09,Explainer: Prescription drugs become a target in Trump's trade war,U.S. President Donald Trump late on Tuesday reiterated he would impose tariffs on imports of pharmaceutical products that have long been spared from past trade disputes due to the potential for harm to patients.,reuters.com,https://www.reuters.com/business/healthcare-pharmaceuticals/prescription-drugs-become-target-trumps-trade-war-2025-04-09/,https://images.financialmodelingprep.com/news/explainer-prescription-drugs-become-a-target-in-trumps-trade-20250409.jpg
JNJ,2025-04-15,2025-04-01,2025-04-29,JNJ,,2025-04-09 13:06:51,2025-04-09T13:06:51-04:00,2025-04-09,Healthy Returns: Trump says major pharmaceutical tariffs coming ‘very shortly',"Trump doubled down on plans to soon impose ""major"" pharmaceutical tariffs, while early stage startups dominated digital health funding deals in first quarter.",cnbc.com,https://www.cnbc.com/2025/04/09/healthy-returns-trump-says-major-pharmaceutical-tariffs-coming-soon.html,https://images.financialmodelingprep.com/news/healthy-returns-trump-says-major-pharmaceutical-tariffs-coming-very-20250409.jpg
JNJ,2025-04-15,2025-04-01,2025-04-29,JNJ,,2025-04-09 11:49:00,2025-04-09T11:49:00-04:00,2025-04-09,Why drug stocks are no longer a safe haven from the stock market's turmoil,"Shares of drugmakers were taking a broad beating Wednesday, after President Donald Trump indicated that pharmaceuticals will no longer be excluded from tariffs.",marketwatch.com,https://www.marketwatch.com/story/why-drug-stocks-are-no-longer-a-safe-haven-from-the-stock-markets-turmoil-c566fa39,https://images.financialmodelingprep.com/news/why-drug-stocks-are-no-longer-a-safe-haven-20250409.jpg
JNJ,2025-04-15,2025-04-01,2025-04-29,JNJ,,2025-04-09 11:28:20,2025-04-09T11:28:20-04:00,2025-04-09,This Johnson & Johnson Analyst Turns Bullish On Shifting Focus From Stelara Concerns To Innovative Medicine,"While the consensus seems to underappreciate the trajectory of Johnson & Johnson's JNJ Innovative Medicine business, Goldman Sachs says concerns around the Stelara loss of exclusivity appear overdone.",benzinga.com,https://www.benzinga.com/analyst-ratings/analyst-color/25/04/44716589/this-johnson-johnson-analyst-turns-bullish-on-shifting-focus-from-stelara-concerns-to-innovative-medicine,https://images.financialmodelingprep.com/news/this-johnson-johnson-analyst-turns-bullish-on-shifting-focus-20250409.jpg
JNJ,2025-04-15,2025-04-01,2025-04-29,JNJ,,2025-04-09 10:56:32,2025-04-09T10:56:32-04:00,2025-04-09,"Pharma tariffs unlikely to hit earnings before 2026, analysts say","Potential tariffs on pharmaceuticals under the Trump administration would take more time to have an impact on the sector than investors may realize, analysts at Bank of America believe. US president Donald Trump said on Tuesday that the country would soon be announcing a “major tariff” on pharmaceuticals with the aim of onshoring drug manufacturing.",proactiveinvestors.com,https://www.proactiveinvestors.com/companies/news/1069397,https://images.financialmodelingprep.com/news/pharma-tariffs-unlikely-to-hit-earnings-before-2026-analysts-20250409.jpg
JNJ,2025-04-15,2025-04-01,2025-04-29,JNJ,,2025-04-09 09:50:43,2025-04-09T09:50:43-04:00,2025-04-09,"S&P 500: Pharma Giants Lead Decline as Tariff Threats Rattle Pfizer, Merck, Johnson & Johnson","Pharmaceutical stocks tumble as Trump announces imminent “major tariff” on imported drugs. Pfizer, Merck, and Johnson & Johnson shares drop over 4%, dragging the broader S&P 500 lower.",fxempire.com,https://www.fxempire.com/forecasts/article/sp-500-pharma-giants-lead-decline-as-tariff-threats-rattle-pfizer-merck-johnson-johnson-1510555,https://images.financialmodelingprep.com/news/sp-500-pharma-giants-lead-decline-as-tariff-threats-20250409.jpg
JNJ,2025-04-15,2025-04-01,2025-04-29,JNJ,,2025-04-10 10:20:51,2025-04-10T10:20:51-04:00,2025-04-10,Seeking Clues to Johnson & Johnson (JNJ) Q1 Earnings? A Peek Into Wall Street Projections for Key Metrics,"Evaluate the expected performance of Johnson & Johnson (JNJ) for the quarter ended March 2025, looking beyond the conventional Wall Street top-and-bottom-line estimates and examining some of its key metrics for better insight.",zacks.com,https://www.zacks.com/stock/news/2443268/seeking-clues-to-johnson-johnson-jnj-q1-earnings-a-peek-into-wall-street-projections-for-key-metrics?cid=CS-STOCKNEWSAPI-FT-fundamental_analysis|nfm_preview-2443268,https://images.financialmodelingprep.com/news/seeking-clues-to-johnson-johnson-jnj-q1-earnings-a-20250410.jpg
JNJ,2025-04-15,2025-04-01,2025-04-29,JNJ,,2025-04-10 08:05:00,2025-04-10T08:05:00-04:00,2025-04-10,Icotrokinra results show 75% of adolescents with plaque psoriasis achieved completely clear skin and demonstrate favorable safety profile in a once daily pill,"ICONIC-LEAD is the first ever Phase 3 registrational study in moderate-to-severe plaque psoriasis to assess safety and efficacy of a systemic therapy in adolescents and adults simultaneously 84% of adolescents with moderate-to-severe plaque psoriasis treated with investigational icotrokinra achieved clear or almost clear skin (IGA 0/1) at Week 16 SPRING HOUSE, Pa. , April 10, 2025 /PRNewswire/ -- Johnson & Johnson (NYSE: JNJ) today announced new icotrokinra (JNJ-2113) data from a subgroup analysis of ICONIC-LEADa, the first ever Phase 3 registrational study in moderate-to-severe plaque psoriasis (PsO) to assess efficacy and safety of a systemic therapy in adolescents and adults simultaneously.",prnewswire.com,https://www.prnewswire.com/news-releases/icotrokinra-results-show-75-of-adolescents-with-plaque-psoriasis-achieved-completely-clear-skin-and-demonstrate-favorable-safety-profile-in-a-once-daily-pill-302425136.html,https://images.financialmodelingprep.com/news/icotrokinra-results-show-75-of-adolescents-with-plaque-psoriasis-20250410.jpg
JNJ,2025-04-15,2025-04-01,2025-04-29,JNJ,,2025-04-10 05:17:00,2025-04-10T05:17:00-04:00,2025-04-10,Stock Market Sell-Off Shopping Spree: 3 Top Dividend Stocks I Just Bought to Boost My Passive Income,"Stock market sell-offs like the one we're currently experiencing are challenging periods for investors. However, with every challenge comes an opportunity to improve.",fool.com,https://www.fool.com/investing/2025/04/10/stock-market-sell-off-shopping-spree-3-top-dividen/,https://images.financialmodelingprep.com/news/stock-market-selloff-shopping-spree-3-top-dividend-stocks-20250410.jpg
JNJ,2025-04-15,2025-04-01,2025-04-29,JNJ,,2025-04-10 04:45:55,2025-04-10T04:45:55-04:00,2025-04-10,"Autos, pharma, luxury and more: The global sectors soaring after Trump's tariffs walkback","European stocks soared on Thursday after U.S. President Donald Trump's jarring about-turn on most tariffs. Tensions between Washington and Beijing remain high, however, with Trump ratcheting up duties on goods from China to 125% and citing a ""lack of respect.",cnbc.com,https://www.cnbc.com/2025/04/10/autos-pharma-luxury-sectors-soaring-after-trumps-tariffs-walkback.html,https://images.financialmodelingprep.com/news/autos-pharma-luxury-and-more-the-global-sectors-soaring-20250410.jpg
JNJ,2025-04-15,2025-04-01,2025-04-29,JNJ,,2025-04-10 03:51:00,2025-04-10T03:51:00-04:00,2025-04-10,"The Dow Crashed 4,260 Points in 3 Days: Here Are 3 Dow Stocks That Make for No-Brainer Buys Right Now","Long before the S&P 500 became Wall Street's benchmark index, the iconic Dow Jones Industrial Average (^DJI 7.87%) was viewed as the best barometer of the stock market's health. Since its inception in May 1896, the Dow has evolved from a 12-stock, industrial-focused index to one that now houses 30 time-tested, multinational companies.",fool.com,https://www.fool.com/investing/2025/04/10/dow-crash-4260-points-3-dow-stocks-no-brainer-buys/,https://images.financialmodelingprep.com/news/the-dow-crashed-4260-points-in-3-days-here-20250410.jpg
JNJ,2025-04-15,2025-04-01,2025-04-29,JNJ,,2025-04-11 18:56:59,2025-04-11T18:56:59-04:00,2025-04-11,"Jim Cramer's week ahead: Earnings from Goldman Sachs, Johnson & Johnson and Netflix","CNBC's Jim Cramer on Friday told investors which market-moving events to follow next week. He pinpointed earnings reports from major banks like Goldman Sachs, as well as Johnson & Johnson and Netflix,",cnbc.com,https://www.cnbc.com/2025/04/11/jim-cramers-week-ahead-earnings-from-goldman-sachs-netflix.html,https://images.financialmodelingprep.com/news/jim-cramers-week-ahead-earnings-from-goldman-sachs-johnson-johnson-20250411.jpg
JNJ,2025-04-15,2025-04-01,2025-04-29,JNJ,,2025-04-11 12:46:42,2025-04-11T12:46:42-04:00,2025-04-11,"Johnson & Johnson: Fairly Valued, But Recession-Resilient","Johnson & Johnson offers stability and limited downside risk, making it a solid investment in volatile markets, despite not being a high-growth stock. The company's fiscal 2024 results showed moderate growth in sales and earnings, with notable performance in the oncology and cardiovascular segments. Analysts expect low-to-mid single-digit growth for Johnson & Johnson, with a focus on operational efficiency and share buybacks to boost the bottom line.",seekingalpha.com,https://seekingalpha.com/article/4774546-johnson-and-johnson-fairly-valued-but-recession-resilient,https://images.financialmodelingprep.com/news/johnson-johnson-fairly-valued-but-recessionresilient-20250411.jpg
JNJ,2025-04-15,2025-04-01,2025-04-29,JNJ,,2025-04-11 12:35:35,2025-04-11T12:35:35-04:00,2025-04-11,"Buy, Sell or Hold J&J Stock? Key Tips Ahead of Q1 Earnings",JNJ's Innovative Medicines unit sales are expected to have been driven by drugs like Darzalex and Tremfya. We do not expect any improvement in MedTech sales.,zacks.com,https://www.zacks.com/stock/news/2447840/buy-sell-or-hold-j-j-stock-key-tips-ahead-of-q1-earnings?cid=CS-STOCKNEWSAPI-FT-analyst_blog|most_popular_stocks-2447840,https://images.financialmodelingprep.com/news/buy-sell-or-hold-jj-stock-key-tips-ahead-20250411.jpg
JNJ,2025-04-15,2025-04-01,2025-04-29,JNJ,,2025-04-11 10:30:55,2025-04-11T10:30:55-04:00,2025-04-11,"Trump's pharmaceutical tariffs could raise costs for patients, worsen drug shortages","President Donald Trump's planned tariffs on pharmaceuticals imported into the U.S. could have wide-ranging consequences on the drug supply chain, manufacturers and American patients, some experts told CNBC.  The tariffs could disrupt the complex pharmaceutical supply chain, potentially driving up the prices of drugs in the U.S. and exacerbating shortages of critical medicine.",cnbc.com,https://www.cnbc.com/2025/04/11/trump-pharmaceutical-tariffs-may-raise-costs-worsen-drug-shortages.html,https://images.financialmodelingprep.com/news/trumps-pharmaceutical-tariffs-could-raise-costs-for-patients-worsen-20250411.jpg
JNJ,2025-04-15,2025-04-01,2025-04-29,JNJ,,2025-04-11 08:28:00,2025-04-11T08:28:00-04:00,2025-04-11,This Pharma Giant Will Invest $23 Billion in the U.S. It's a Sign Trump's Tariffs Are Working.,The Company spend billions to produce 100% of its key medicines for Americans in the U.S.,barrons.com,https://www.barrons.com/articles/novartis-stock-price-pharma-tariffs-6e30cb9e,https://images.financialmodelingprep.com/news/this-pharma-giant-will-invest-23-billion-in-the-20250411.jpg
JNJ,2025-04-15,2025-04-01,2025-04-29,JNJ,,2025-04-11 04:25:00,2025-04-11T04:25:00-04:00,2025-04-11,2 Top Dividend Stocks to Buy Right Now,Microsoft (MSFT -2.33%) and Johnson & Johnson (JNJ -1.64%) are leading companies in their respective industries. They both have impressive track records and have made their long-term shareholders significantly richer.,fool.com,https://www.fool.com/investing/2025/04/11/2-top-dividend-stocks-to-buy-right-now/,https://images.financialmodelingprep.com/news/2-top-dividend-stocks-to-buy-right-now-20250411.jpg
JNJ,2025-04-15,2025-04-01,2025-04-29,JNJ,,2025-04-14 14:03:52,2025-04-14T14:03:52-04:00,2025-04-14,Trump Says Pharmaceutical Tariffs Coming in Near Future,"President Donald Trump said tariffs on pharmaceuticals will be coming in the “not too distant future” and fit in the category of tariffs imposed on cars, steel, and aluminum. Trump spoke with reporters Monday in the Oval Office.",youtube.com,https://www.youtube.com/watch?v=_uqmK3nn4nI,https://images.financialmodelingprep.com/news/trump-says-pharmaceutical-tariffs-coming-in-near-future-20250414.jpg
JNJ,2025-04-15,2025-04-01,2025-04-29,JNJ,,2025-04-14 12:26:25,2025-04-14T12:26:25-04:00,2025-04-14,Trump says US pharma tariffs coming in not-too-distant future,U.S. President Donald Trump said on Monday that he expects to impose tariffs on imported pharmaceuticals in the not-too-distant future.,reuters.com,https://www.reuters.com/business/healthcare-pharmaceuticals/trump-says-us-pharma-tariffs-coming-not-too-distant-future-2025-04-14/,https://images.financialmodelingprep.com/news/trump-says-us-pharma-tariffs-coming-in-nottoodistant-future-20250414.jpg
JNJ,2025-04-15,2025-04-01,2025-04-29,JNJ,,2025-04-14 10:05:00,2025-04-14T10:05:00-04:00,2025-04-14,"Johnson & Johnson's Oral IL-23, Icotrokinra, Poised to Redefine the Psoriasis Treatment Landscape Following Positive Phase 3 Data, According to Spherix Global Insights","Perceived first-line utility, patient pool expansion, and paradigm-shifting potential distinguish Icotrokinra in the eyes of US dermatologists Perceived first-line utility, patient pool expansion, and paradigm-shifting potential distinguish Icotrokinra in the eyes of US dermatologists",globenewswire.com,https://www.globenewswire.com/news-release/2025/04/14/3061069/0/en/Johnson-Johnson-s-Oral-IL-23-Icotrokinra-Poised-to-Redefine-the-Psoriasis-Treatment-Landscape-Following-Positive-Phase-3-Data-According-to-Spherix-Global-Insights.html,https://images.financialmodelingprep.com/news/johnson-johnsons-oral-il23-icotrokinra-poised-to-redefine-the-20250414.jpg
JNJ,2025-04-15,2025-04-01,2025-04-29,JNJ,,2025-04-15 20:05:48,2025-04-15T20:05:48-04:00,2025-04-15,"Portfolio positioning amid tariff uncertainty, Johnson & Johnson's Q1 earnings beat, HPE stock jumps","Josh speaks to experts about the state of markets amid President Trump's tariff pause and trade tensions escalating with China. Other topics include bank earnings, Johnson & Johnson reporting a Q1 earnings beat, and HPE stock jumping on Elliott Management reportedly taking a $1.5 billion stake in the company.",youtube.com,https://www.youtube.com/watch?v=uX_M-UaFi2U,https://images.financialmodelingprep.com/news/portfolio-positioning-amid-tariff-uncertainty-johnson-johnsons-q1-earnings-20250415.jpg
JNJ,2025-04-15,2025-04-01,2025-04-29,JNJ,,2025-04-15 15:30:28,2025-04-15T15:30:28-04:00,2025-04-15,"J&J's Spravato momentum points to commercial viability of psychedelics for mental health, analysts say","Another quarter of consistent growth for Johnson & Johnson (NYSE:JNJ)'s esketamine nasal spray Spravato bodes well for other psychedelics, analysts at Jefferies believe. They see consistent quarter-over-quarter Spravato sales growth supporting the notion psychedelics can become commercially viable in mental health.",proactiveinvestors.com,https://www.proactiveinvestors.com/companies/news/1069746,https://images.financialmodelingprep.com/news/jjs-spravato-momentum-points-to-commercial-viability-of-psychedelics-20250415.jpg
JNJ,2025-04-15,2025-04-01,2025-04-29,JNJ,,2025-04-15 15:00:00,2025-04-15T15:00:00-04:00,2025-04-15,Two New Dividend Picks To Help You Navigate Tariffs And Uncertainty -- One Yields 7%+,"The acquisitions of Alexandria Real Estate and Unilever enhance sector and geographical diversification, increase dividend income capacity, and reduce portfolio volatility, aligning with The Dividend Income Accelerator Portfolio's goals. Alexandria Real Estate offers a strong Dividend Yield [FWD] of 7.16%, robust financials, and is undervalued, making it a strategic addition to our portfolio. Unilever's fair Valuation and low 24M Beta Factor of 0.11 further reduce portfolio volatility and enhance risk-adjusted returns.",seekingalpha.com,https://seekingalpha.com/article/4774739-two-new-dividend-picks-to-help-you-navigate-tariffs-and-uncertainty-one-yields-7-percent-plus,https://images.financialmodelingprep.com/news/two-new-dividend-picks-to-help-you-navigate-tariffs-20250415.jpg
JNJ,2025-04-15,2025-04-01,2025-04-29,JNJ,,2025-04-15 13:03:46,2025-04-15T13:03:46-04:00,2025-04-15,Johnson & Johnson tops Wall Street expectations in Q1,Johnson & Johnson (JNJ) reported stronger-than-expected earnings. Goldman Sachs Global Investment Research head of the healthcare business unit Asad Haider joins Catalysts with Madison Mills and StoneX senior adviser Jon Hilsenrath to take a closer look at the earnings print and Johnson & Johnson's position as US President Trump pushes for tariffs on pharmaceutical imports.,youtube.com,https://www.youtube.com/watch?v=7cptL8XIXOw,https://images.financialmodelingprep.com/news/johnson-johnson-tops-wall-street-expectations-in-q1-20250415.jpg
JNJ,2025-04-15,2025-04-01,2025-04-29,JNJ,,2025-04-15 12:42:29,2025-04-15T12:42:29-04:00,2025-04-15,Johnson & Johnson (JNJ) Q1 2025 Earnings Call Transcript,"Johnson & Johnson (NYSE:JNJ ) Q1 2025 Earnings Conference Call April 15, 2025 8:30 AM ET Company Participants Jessica Moore - Vice President, Investor Relations Joaquin Duato - Chairman and Chief Executive Officer John Reed - EVP, Innovative Medicine, R&D Joseph Wolk - EVP, Chief Financial Officer Jennifer Taubert - EVP, Worldwide Chairman, Innovative Medicine Tim Schmid - EVP, Worldwide Chairman, MedTech Conference Call Participants Lawrence Biegelsen - Wells Fargo Chris Schott - JPMorgan Asad Haider - Goldman Sachs Danielle Antalffy - UBS Terence Flynn - Morgan Stanley Joanne Wuensch - Citibank Vamil Divan - Guggenheim Securities Matt Miksic - Barclays Tim Anderson - Bank of America Operator Good morning, and welcome to Johnson & Johnson's First Quarter 2025 Earnings Conference Call. All participants will be in listen-only mode until the question-and-answer session of the conference.",seekingalpha.com,https://seekingalpha.com/article/4775320-johnson-and-johnson-jnj-q1-2025-earnings-call-transcript,https://images.financialmodelingprep.com/news/johnson-johnson-jnj-q1-2025-earnings-call-transcript-20250415.jpg
JNJ,2025-04-15,2025-04-01,2025-04-29,JNJ,,2025-04-15 12:15:34,2025-04-15T12:15:34-04:00,2025-04-15,"JNJ Tops Q1 Earnings, Ups '25 Sales View to Include Intra-Cellular Deal",J&J beats first-quarter earnings and sales estimates. It raises sales guidance for 2025 to reflect the addition of Caplyta from the Intra-Cellular acquisition.,zacks.com,https://www.zacks.com/stock/news/2449268/jnj-tops-q1-earnings-ups-25-sales-view-to-include-intra-cellular-deal?cid=CS-STOCKNEWSAPI-FT-analyst_blog|earnings_article-2449268,https://images.financialmodelingprep.com/news/jnj-tops-q1-earnings-ups-25-sales-view-to-20250415.jpg
JNJ,2025-04-15,2025-04-01,2025-04-29,JNJ,,2025-04-15 12:05:34,2025-04-15T12:05:34-04:00,2025-04-15,Import Prices Turn Negative for First Time Since September,"New economic data is out this morning, some of it reflecting conditions prior to our current tariff realities. We also see Q1 earnings results continue to ramp up, but we won't have the spigots open completely til next week.",zacks.com,https://www.zacks.com/stock/news/2449263/import-prices-turn-negative-for-first-time-since-september?cid=CS-STOCKNEWSAPI-FT-economic_highlights-2449263,https://images.financialmodelingprep.com/news/import-prices-turn-negative-for-first-time-since-september-20250415.jpg
JNJ,2025-04-15,2025-04-01,2025-04-29,JNJ,,2025-04-15 11:21:04,2025-04-15T11:21:04-04:00,2025-04-15,"Import Prices, Empire State Come In Mild; Q1 Earnings Beats Abound","Pre-markets are down somewhat, following yesterday's +3/4-percent gain on the Dow and the S&P 500, +2/3-percent gain for the Nasdaq.",zacks.com,https://www.zacks.com/stock/news/2449207/import-prices-empire-state-come-in-mild-q1-earnings-beats-abound?cid=CS-STOCKNEWSAPI-FT-ahead_of_wall_street-2449207,https://images.financialmodelingprep.com/news/import-prices-empire-state-come-in-mild-q1-earnings-20250415.jpg
JNJ,2025-04-15,2025-04-01,2025-04-29,JNJ,,2025-04-15 11:06:51,2025-04-15T11:06:51-04:00,2025-04-15,J&J Expects Tariffs to Cost Company $400 Million,Johnson & Johnson is holding its earnings outlook steady despite President Donald Trump signaling he could put tariffs on the pharmaceutical industry. The administration announced earlier it would conduct an investigation into drug imports.,youtube.com,https://www.youtube.com/watch?v=ZOFpgn6Grzw,https://images.financialmodelingprep.com/news/jj-expects-tariffs-to-cost-company-400-million-20250415.jpg
JNJ,2025-04-15,2025-04-01,2025-04-29,JNJ,,2025-04-15 10:53:10,2025-04-15T10:53:10-04:00,2025-04-15,Johnson & Johnson beats on top and bottom lines,CNBC's Angelica Peebles joins 'Squawk on the Street' to discuss J&J's most recent earnings report.,youtube.com,https://www.youtube.com/watch?v=N1UbYRgnqA8,https://images.financialmodelingprep.com/news/johnson-johnson-beats-on-top-and-bottom-lines-20250415.jpg
JNJ,2025-04-15,2025-04-01,2025-04-29,JNJ,,2025-04-15 10:43:12,2025-04-15T10:43:12-04:00,2025-04-15,Johnson & Johnson: First Look At Q1 Earnings - Solid Quarter Will Calm Nerves,"Johnson & Johnson's Q1 2025 earnings show a 2.4% sales increase and a significant EPS rise, despite litigation charges impacting GAAP figures. The MedTech division grew 4.1%, driven by acquisitions, while Pharmaceuticals saw a 4.2% increase, despite challenges like Stelara's patent expiry. JNJ raised its full-year revenue guidance and increased its dividend, reflecting confidence in long-term growth despite short-term litigation and tariff uncertainties.",seekingalpha.com,https://seekingalpha.com/article/4775271-johnson-and-johnson-first-look-at-q1-earnings-solid-quarter-will-calm-nerves,https://images.financialmodelingprep.com/news/johnson-johnson-first-look-at-q1-earnings-solid-quarter-20250415.jpg
JNJ,2025-04-15,2025-04-01,2025-04-29,JNJ,,2025-04-15 10:31:08,2025-04-15T10:31:08-04:00,2025-04-15,"Compared to Estimates, Johnson & Johnson (JNJ) Q1 Earnings: A Look at Key Metrics","While the top- and bottom-line numbers for Johnson & Johnson (JNJ) give a sense of how the business performed in the quarter ended March 2025, it could be worth looking at how some of its key metrics compare to Wall Street estimates and year-ago values.",zacks.com,https://www.zacks.com/stock/news/2449062/compared-to-estimates-johnson-johnson-jnj-q1-earnings-a-look-at-key-metrics?cid=CS-STOCKNEWSAPI-FT-fundamental_analysis|nfm-2449062,https://images.financialmodelingprep.com/news/compared-to-estimates-johnson-johnson-jnj-q1-earnings-a-20250415.jpg
JNJ,2025-04-15,2025-04-01,2025-04-29,JNJ,,2025-04-15 10:30:06,2025-04-15T10:30:06-04:00,2025-04-15,"JNJ Raises Guidance Despite Tariffs, ACI Guidance Slump, GM Downgrades",Johnson & Johnson (JNJ) boosted its full-year guidance while taking tariffs into account. Diane King Hall talks about its new acquisitions as a reason behind company confidence.,youtube.com,https://www.youtube.com/watch?v=7-8Y5MfwOck,https://images.financialmodelingprep.com/news/jnj-raises-guidance-despite-tariffs-aci-guidance-slump-gm-20250415.jpg
JNJ,2025-04-15,2025-04-01,2025-04-29,JNJ,,2025-04-15 09:43:00,2025-04-15T09:43:00-04:00,2025-04-15,"Johnson & Johnson tops Q1 expectations, lifts 2025 sales outlook","Johnson & Johnson (NYSE:JNJ) reported its first quarter earnings, with both revenue and profit beating Wall Street expectations driven by strong sales in its oncology portfolio, especially the multiple myeloma drug Darzalex. Revenue was up 2.4% year-over-year at $21.89 billion, ahead of estimates of $21.56 billion.",proactiveinvestors.com,https://www.proactiveinvestors.com/companies/news/1069720,https://images.financialmodelingprep.com/news/johnson-johnson-tops-q1-expectations-lifts-2025-sales-outlook-20250415.jpg
JNJ,2025-04-15,2025-04-01,2025-04-29,JNJ,,2025-04-15 08:49:08,2025-04-15T08:49:08-04:00,2025-04-15,"Johnson & Johnson Skids Despite First-Quarter Beat, Sales Guidance Hike","Johnson & Johnson stock fell alongside the broader market, despite beating first-quarter calls and hiking its 2025 sales guidance.",investors.com,https://www.investors.com/news/technology/johnson-johnson-stock-johnson-johnson-earnings-q1-2025/,https://images.financialmodelingprep.com/news/johnson-johnson-skids-despite-firstquarter-beat-sales-guidance-hike-20250415.jpg
JNJ,2025-04-15,2025-04-01,2025-04-29,JNJ,,2025-04-15 08:35:29,2025-04-15T08:35:29-04:00,2025-04-15,Johnson & Johnson (JNJ) Q1 Earnings and Revenues Beat Estimates,"Johnson & Johnson (JNJ) came out with quarterly earnings of $2.77 per share, beating the Zacks Consensus Estimate of $2.57 per share. This compares to earnings of $2.71 per share a year ago.",zacks.com,https://www.zacks.com/stock/news/2448896/johnson-johnson-jnj-q1-earnings-and-revenues-beat-estimates?cid=CS-STOCKNEWSAPI-FT-tale_of_the_tape|yseop_template_4-2448896,https://images.financialmodelingprep.com/news/johnson-johnson-jnj-q1-earnings-and-revenues-beat-estimates-20250415.jpg
JNJ,2025-04-15,2025-04-01,2025-04-29,JNJ,,2025-04-15 08:11:00,2025-04-15T08:11:00-04:00,2025-04-15,"Johnson & Johnson raised its sales outlook, even with tariff costs included","Johnson & Johnson beat Wall Street's expectations for first-quarter profit and revenue on Tuesday, as strong growth in the U.S. offset weakness internationally.",marketwatch.com,https://www.marketwatch.com/story/johnson-johnson-shares-rise-on-q1-profit-and-revenue-beat-and-raised-guidance-11a83186,https://images.financialmodelingprep.com/news/johnson-johnson-raised-its-sales-outlook-even-with-tariff-20250415.jpg
JNJ,2025-04-15,2025-04-01,2025-04-29,JNJ,,2025-04-15 07:28:13,2025-04-15T07:28:13-04:00,2025-04-15,Johnson & Johnson CFO on earnings: Guidance has 'a lot more than meets the eye',"Joseph Wolk, Johnson & Johnson EVP and CFO, joins 'Squawk Box' to discuss the company's quarterly earnings results, the company's planned expenditures, and much more.",youtube.com,https://www.youtube.com/watch?v=PaEejqjIsRs,https://images.financialmodelingprep.com/news/johnson-johnson-cfo-on-earnings-guidance-has-a-lot-20250415.jpg
JNJ,2025-04-15,2025-04-01,2025-04-29,JNJ,,2025-04-15 07:06:02,2025-04-15T07:06:02-04:00,2025-04-15,"Johnson & Johnson Tops Q1 Estimates, Lifts Full-Year Sales Outlook",Johnson & Johnson (JNJ) on Tuesday reported better-than-expected first-quarter results and lifted its sales forecast for the full year.,investopedia.com,https://www.investopedia.com/johnson-and-johnson-q1-fy2025-earnings-11714823,https://images.financialmodelingprep.com/news/johnson-johnson-tops-q1-estimates-lifts-fullyear-sales-outlook-20250415.jpg
JNJ,2025-04-15,2025-04-01,2025-04-29,JNJ,,2025-04-15 06:53:00,2025-04-15T06:53:00-04:00,2025-04-15,J&J Increases Outlook After Beating 1Q Expectations,"Johnson & Johnson now expects sales of up to $91.8 billion in 2025, compared with a prior view of up to $90 billion.",wsj.com,https://www.wsj.com/business/earnings/j-j-increases-outlook-after-beating-1q-expectations-36cda438,https://images.financialmodelingprep.com/news/jj-increases-outlook-after-beating-1q-expectations-20250415.jpg
JNJ,2025-04-15,2025-04-01,2025-04-29,JNJ,,2025-04-15 06:23:50,2025-04-15T06:23:50-04:00,2025-04-15,J&J beats Wall Street quarterly sales and profit estimates on cancer drug sales,"Johnson & Johnson on Tuesday reported first-quarter revenue and profit above Wall Street estimates, driven again by strong sales of its cancer treatments including multiple myeloma medicine Darzalex.",reuters.com,https://www.reuters.com/business/healthcare-pharmaceuticals/jj-beats-wall-street-quarterly-sales-profit-estimates-cancer-drug-sales-2025-04-15/,https://images.financialmodelingprep.com/news/jj-beats-wall-street-quarterly-sales-and-profit-estimates-20250415.jpg
JNJ,2025-04-15,2025-04-01,2025-04-29,JNJ,,2025-04-15 06:20:00,2025-04-15T06:20:00-04:00,2025-04-15,Johnson & Johnson Reports Q1 2025 Results,"NEW BRUNSWICK, N.J.--(BUSINESS WIRE)--Johnson & Johnson (NYSE: JNJ) today announced results for first-quarter 2025. “The power of Johnson & Johnson's uniquely diversified portfolio was on full display this quarter, with strong operational sales growth reinforcing our confidence in 2025 guidance,” said Joaquin Duato, Chairman and Chief Executive Officer, Johnson & Johnson. “During the quarter, we fortified our position as an innovation powerhouse with major advancements across our pi.",businesswire.com,https://www.businesswire.com/news/home/20250414807799/en/Johnson-Johnson-Reports-Q1-2025-Results/,https://images.financialmodelingprep.com/news/johnson-johnson-reports-q1-2025-results-20250415.jpg
JNJ,2025-04-15,2025-04-01,2025-04-29,JNJ,,2025-04-15 03:33:01,2025-04-15T03:33:01-04:00,2025-04-15,Johnson & Johnson Gears Up For Q1 Print; Here Are The Recent Forecast Changes From Wall Street's Most Accurate Analysts,"Johnson & Johnson JNJ will release earnings results for the first quarter, before the opening bell on Tuesday, April 15.",benzinga.com,https://www.benzinga.com/25/04/44806571/johnson-here-are-the-recent-forecast-changes-from-wall-streets-most-accurate-analysts,https://images.financialmodelingprep.com/news/johnson-johnson-gears-up-for-q1-print-here-are-20250415.jpg
JNJ,2025-04-15,2025-04-01,2025-04-29,JNJ,,2025-04-16 19:35:30,2025-04-16T19:35:30-04:00,2025-04-16,"Buy These Defensive Stocks After Beating Earnings Expectations?: ACI, JNJ",Johnson & Johnson (JNJ) and Albertsons Companies' (ACI) stock have provided a pleasant hedge against market volatility and were able to exceed their quarterly expectations on Wednesday.,zacks.com,https://www.zacks.com/commentary/2450238/buy-these-defensive-stocks-after-beating-earnings-expectations-aci-jnj?cid=CS-STOCKNEWSAPI-FT-investment_ideas-2450238,https://images.financialmodelingprep.com/news/buy-these-defensive-stocks-after-beating-earnings-expectations-aci-20250416.jpg
JNJ,2025-04-15,2025-04-01,2025-04-29,JNJ,,2025-04-16 16:28:00,2025-04-16T16:28:00-04:00,2025-04-16,Johnson & Johnson to Participate in the 2025 RBC Capital Markets Global Healthcare Conference,"NEW BRUNSWICK, N.J.--(BUSINESS WIRE)--Johnson & Johnson (NYSE: JNJ) will participate in the 2025 RBC Capital Markets Global Healthcare Conference on Tuesday, May 20th. Management will participate in a Fireside Chat at 1:35 p.m. Eastern Time. This live audio webcast will be available to investors and other interested parties by accessing the Johnson & Johnson website at www.investor.jnj.com. The audio webcast replay will be available approximately 48 hours after the webcast.",businesswire.com,https://www.businesswire.com/news/home/20250416370813/en/Johnson-Johnson-to-Participate-in-the-2025-RBC-Capital-Markets-Global-Healthcare-Conference/,https://images.financialmodelingprep.com/news/johnson-johnson-to-participate-in-the-2025-rbc-capital-20250416.jpg
JNJ,2025-04-15,2025-04-01,2025-04-29,JNJ,,2025-04-16 12:51:03,2025-04-16T12:51:03-04:00,2025-04-16,Healthy Returns: What drugmakers are saying about Trump's looming pharmaceutical tariffs,"What Johnson & Johnson and Eli Lilly are saying about Trump's pharmaceutical tariffs, and Dexcom scores FDA approval for its glucose monitoring system.",cnbc.com,https://www.cnbc.com/2025/04/16/healthy-returns-drugmakers-comment-on-trumps-pharmaceutical-tariffs.html,https://images.financialmodelingprep.com/news/healthy-returns-what-drugmakers-are-saying-about-trumps-looming-20250416.jpg
JNJ,2025-04-15,2025-04-01,2025-04-29,JNJ,,2025-04-16 11:00:44,2025-04-16T11:00:44-04:00,2025-04-16,"ETFs in Focus Post JNJ's Q1 Earnings Beat, Dividend Hike","Johnson & Johnson reports strong first-quarter 2025 results, raises revenue guidance and boosts its quarterly dividends.",zacks.com,https://www.zacks.com/stock/news/2449981/etfs-in-focus-post-jnj-s-q1-earnings-beat-dividend-hike?cid=CS-STOCKNEWSAPI-FT-etf_news_and_commentary-2449981,https://images.financialmodelingprep.com/news/etfs-in-focus-post-jnjs-q1-earnings-beat-dividend-20250416.jpg
JNJ,2025-04-15,2025-04-01,2025-04-29,JNJ,,2025-04-16 07:58:10,2025-04-16T07:58:10-04:00,2025-04-16,Johnson & Johnson Earnings Were More Good Than Bad—Time to Buy?,"On the one hand, the company beat on the top and bottom lines and offered better-than-expected guidance. On the other hand, JNJ acknowledged the likelihood of a $400 million tariff hit on the company's medical device business that will impact business in the short term.",marketbeat.com,https://www.marketbeat.com/originals/johnson-and-johnson-earnings-were-more-good-than-bad-time-to-buy/,https://images.financialmodelingprep.com/news/johnson-johnson-earnings-were-more-good-than-badtime-to-buy-20250416.jpg
JNJ,2025-04-15,2025-04-01,2025-04-29,JNJ,,2025-04-17 11:19:34,2025-04-17T11:19:34-04:00,2025-04-17,3 High-Yield Dividend All-Stars to Buy Right Now,The good news for investors seeking high-yield dividend stocks to buy right now is that there are a number of top options for investors to consider in the high-yield dividend world.,247wallst.com,https://247wallst.com/investing/2025/04/17/3-high-yield-dividend-all-stars-to-buy-right-now/,https://images.financialmodelingprep.com/news/3-highyield-dividend-allstars-to-buy-right-now-20250417.jpg
JNJ,2025-04-15,2025-04-01,2025-04-29,JNJ,,2025-04-17 09:05:35,2025-04-17T09:05:35-04:00,2025-04-17,Here's How You Should Play JNJ Stock After Q1 Earnings Beat,Those who own JNJ stock may stay invested for some time to see how the company achieves growth in 2025 amid the various challenges.,zacks.com,https://www.zacks.com/stock/news/2450449/here-s-how-you-should-play-jnj-stock-after-q1-earnings-beat?cid=CS-STOCKNEWSAPI-FT-analyst_blog|most_popular_stocks-2450449,https://images.financialmodelingprep.com/news/heres-how-you-should-play-jnj-stock-after-q1-20250417.jpg
JNJ,2025-04-15,2025-04-01,2025-04-29,JNJ,,2025-04-17 08:05:00,2025-04-17T08:05:00-04:00,2025-04-17,Why Most Dividend Retirement Strategies Fail: How To Retire With Dividends,"Most high-yield strategies are ticking time bombs. Don't get wiped out when the next downturn hits. Discover the only portfolio blend that can deliver sustainable and rising dividends through inflation, recessions, and even currency collapse.",seekingalpha.com,https://seekingalpha.com/article/4775845-why-most-dividend-retirement-strategies-fail,https://images.financialmodelingprep.com/news/why-most-dividend-retirement-strategies-fail-how-to-retire-20250417.jpg
JNJ,2025-04-15,2025-04-01,2025-04-29,JNJ,,2025-04-17 07:42:50,2025-04-17T07:42:50-04:00,2025-04-17,The Relief Rally Is Over: 4 Incredible Dividend Monarchs Are Our Safest Ideas Now,"While it was fun while it lasted, as we have discussed before, inevitably, after vicious sell-offs like the one we saw from the market peak in February, which pushed the S&P 500 and the Nasdaq quickly into a brief bear market 20% decline territory, there is the potential for stunning bear market rallies.",247wallst.com,https://247wallst.com/investing/2025/04/17/the-relief-rally-is-over-4-incredible-dividend-monarchs-are-our-best-ideas-now/,https://images.financialmodelingprep.com/news/the-relief-rally-is-over-4-incredible-dividend-monarchs-20250417.jpg
JNJ,2025-04-15,2025-04-01,2025-04-29,JNJ,,2025-04-17 04:51:00,2025-04-17T04:51:00-04:00,2025-04-17,4 Reasons Johnson & Johnson Could Be the Perfect Stock to Own in Today's Turbulent Market,"It's less than four months into the year, and many investors are already exhausted. The wild stock market swings fueled by the Trump administration's tariffs are to blame.",fool.com,https://www.fool.com/investing/2025/04/17/4-reasons-johnson-johnson-could-be-the-perfect-sto/,https://images.financialmodelingprep.com/news/4-reasons-johnson-johnson-could-be-the-perfect-stock-to-20250417.jpg
JNJ,2025-04-15,2025-04-01,2025-04-29,JNJ,,2025-04-17 04:07:00,2025-04-17T04:07:00-04:00,2025-04-17,This Super-Safe High-Yield Stock Just Extended Its Dividend Growth Streak to 63 Years in a Row,"Johnson & Johnson (JNJ 0.22%) continues to treat its investors like royalty. The healthcare behemoth recently gave them another raise, increasing its dividend payment by 4.8%.",fool.com,https://www.fool.com/investing/2025/04/17/this-super-safe-high-yield-stock-just-extended-its/,https://images.financialmodelingprep.com/news/this-supersafe-highyield-stock-just-extended-its-dividend-growth-20250417.jpg
JNJ,2025-04-15,2025-04-01,2025-04-29,JNJ,,2025-04-18 08:47:28,2025-04-18T08:47:28-04:00,2025-04-18,One Sector Paying Big Dividends Is Off to the Best Start in 25 Years Despite Tariffs,"Investors love dividend stocks, especially the high-yield variety, because they offer a significant income stream and have massive total return potential.",247wallst.com,https://247wallst.com/investing/2025/04/18/one-sector-paying-big-dividends-is-off-to-the-best-start-in-25-years-despite-tariffs/,https://images.financialmodelingprep.com/news/one-sector-paying-big-dividends-is-off-to-the-20250418.jpg
JNJ,2025-04-15,2025-04-01,2025-04-29,JNJ,,2025-04-18 07:00:00,2025-04-18T07:00:00-04:00,2025-04-18,Johnson & Johnson Pivots Its AI Strategy,The company is making a shift to focus on only the highest-value GenAI use cases and shut down pilots that were redundant or underdelivering.,wsj.com,https://www.wsj.com/articles/johnson-johnson-pivots-its-ai-strategy-a9d0631f,https://images.financialmodelingprep.com/news/johnson-johnson-pivots-its-ai-strategy-20250418.jpg
JNJ,2025-04-15,2025-04-01,2025-04-29,JNJ,,2025-04-19 10:30:00,2025-04-19T10:30:00-04:00,2025-04-19,3 Top Dividend Stocks Yielding Over 3% to Buy With $500 Right Now,Dividend stocks can be fantastic investments. The best ones pay an attractive and growing stream of dividend income while also delivering healthy stock price appreciation over the long term.,fool.com,https://www.fool.com/investing/2025/04/19/3-top-dividend-stocks-yielding-over-3-to-buy-with/,https://images.financialmodelingprep.com/news/3-top-dividend-stocks-yielding-over-3-to-buy-20250419.jpg
JNJ,2025-04-15,2025-04-01,2025-04-29,JNJ,,2025-04-20 07:30:00,2025-04-20T07:30:00-04:00,2025-04-20,2 Recession-Proof Stocks to Buy With a Better Credit Rating Than the U.S. Government,"In 2011, following the difficulty caused by the Great Recession, S&P Global Ratings (formerly Standard & Poor's) downgraded the long-term credit outlook of the United States from its highest designation of AAA to AA+, citing budgetary issues. Fitch once again downgraded U.S. credit in 2023 and Moody's recently suggested it's contemplating a similar move.",fool.com,https://www.fool.com/investing/2025/04/20/2-recession-proof-stocks-to-buy-with-a-better-cred/,https://images.financialmodelingprep.com/news/2-recessionproof-stocks-to-buy-with-a-better-credit-20250420.jpg
JNJ,2025-04-15,2025-04-01,2025-04-29,JNJ,,2025-04-21 09:36:00,2025-04-21T09:36:00-04:00,2025-04-21,Johnson & Johnson unveils highly anticipated and potential practice-changing data in bladder cancer treatment at AUA,"TAR-200 monotherapy shows highest complete response with sustained benefits in 12-month data from Phase 2b SunRISe-1 study (Cohort 2) Compelling first results from Cohort 4 of Phase 2b SunRISe-1 study show potential of TAR-200 monotherapy in patients with papillary-only, high-risk non-muscle invasive bladder cancer RARITAN, N.J. , April 21, 2025 /PRNewswire/ -- Johnson & Johnson (NYSE: JNJ) announced today that new data from its leading oncology pipeline will be presented at the American Urological Association (AUA) 2025 Annual Meeting, taking place April 26-29 in Las Vegas.",prnewswire.com,https://www.prnewswire.com/news-releases/johnson--johnson-unveils-highly-anticipated-and-potential-practice-changing-data-in-bladder-cancer-treatment-at-aua-302433399.html,https://images.financialmodelingprep.com/news/johnson-johnson-unveils-highly-anticipated-and-potential-practicechanging-data-in-20250421.jpg
JNJ,2025-04-15,2025-04-01,2025-04-29,JNJ,,2025-04-21 09:00:44,2025-04-21T09:00:44-04:00,2025-04-21,"LLY, NVO and AMGN Forecast – Pharma Stocks to Open Mixed","The three pharma stocks in this analysis all look a bit mixed in the premarket, after seeing some momentum late last week. This is especially true with LLY, as you will see on the charts.",fxempire.com,https://www.fxempire.com/forecasts/article/lly-nvo-and-amgn-forecast-pharma-stocks-to-open-mixed-1513235,https://images.financialmodelingprep.com/news/lly-nvo-and-amgn-forecast-pharma-stocks-to-open-20250421.jpg
JNJ,2025-04-15,2025-04-01,2025-04-29,JNJ,,2025-04-22 11:13:00,2025-04-22T11:13:00-04:00,2025-04-22,"Eli Lilly, Vertex, AbbVie and More Pharma Stocks to Own as Tariffs Loom",Trump's tariff policy is the latest uncertainty to plague the pharmaceutical sector.,barrons.com,https://www.barrons.com/articles/pharma-stocks-tariffs-e7b96aaa,https://images.financialmodelingprep.com/news/eli-lilly-vertex-abbvie-and-more-pharma-stocks-to-20250422.jpg
JNJ,2025-04-15,2025-04-01,2025-04-29,JNJ,,2025-04-22 07:30:00,2025-04-22T07:30:00-04:00,2025-04-22,Two Stocks To Consider During Market Unrest To Provide Income Stability,"Investors should remain calm amid market volatility and consider buying during price dips, with 2025 expected to see more turbulence. Kenvue's strong brand portfolio and solid liquidity offer price stability and a 3.59% dividend yield, despite potential headwinds from tariffs and economic slowdown. Altria Group, with its 7% yield and Dividend King status, provides stability and potential upside during economic uncertainty, leveraging its pricing power and recession-proof products.",seekingalpha.com,https://seekingalpha.com/article/4776460-two-stocks-to-consider-during-market-unrest-to-provide-income-stability,https://images.financialmodelingprep.com/news/two-stocks-to-consider-during-market-unrest-to-provide-20250422.jpg
JNJ,2025-04-15,2025-04-01,2025-04-29,JNJ,,2025-04-23 11:06:14,2025-04-23T11:06:14-04:00,2025-04-23,"Dividend Kings Down Today: Why Johnson & Johnson (JNJ), Coca-Cola (KO) and Procter & Gamble (PG) Are Sliding",Some analysts expect Procter & Gamble to cut its forecast thanks to uncertainty over spending with global trade tensions.,247wallst.com,https://247wallst.com/investing/2025/04/23/dividend-kings-down-today-why-johnson-johnson-jnj-coca-cola-ko-and-procter-gamble-pg-are-sliding/,https://images.financialmodelingprep.com/news/dividend-kings-down-today-why-johnson-johnson-jnj-cocacola-20250423.jpg
JNJ,2025-04-15,2025-04-01,2025-04-29,JNJ,,2025-04-23 10:46:27,2025-04-23T10:46:27-04:00,2025-04-23,Why Johnson & Johnson (JNJ) is a Top Value Stock for the Long-Term,The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.,zacks.com,https://www.zacks.com/stock/news/2453660/why-johnson-johnson-jnj-is-a-top-value-stock-for-the-long-term?cid=CS-STOCKNEWSAPI-FT-tale_of_the_tape|zacks_education_value_score-2453660,https://images.financialmodelingprep.com/news/why-johnson-johnson-jnj-is-a-top-value-stock-20250423.jpg
JNJ,2025-04-15,2025-04-01,2025-04-29,JNJ,,2025-04-23 09:58:08,2025-04-23T09:58:08-04:00,2025-04-23,2025 Dividend Kings: Weathering Tariff Volatility Better Than The Market,"The Dividend Kings are outperforming the S&P 500 in 2025 by 8.94%. Top performers include National Fuel & Gas (+28.88%), Consolidated Edison (+28.10%), and Middlesex Water Company (+21.00%). Promising Dividend Kings identified in March showed relative outperformance, averaging -3.15% vs. -8.16% for SPY.",seekingalpha.com,https://seekingalpha.com/article/4777162-2025-dividend-kings-weathering-tariff-volatility-better-than-the-market,https://images.financialmodelingprep.com/news/2025-dividend-kings-weathering-tariff-volatility-better-than-the-market-20250423.jpg
JNJ,2025-04-15,2025-04-01,2025-04-29,JNJ,,2025-04-24 10:05:45,2025-04-24T10:05:45-04:00,2025-04-24,Johnson & Johnson (JNJ) is Attracting Investor Attention: Here is What You Should Know,"Johnson & Johnson (JNJ) has been one of the stocks most watched by Zacks.com users lately. So, it is worth exploring what lies ahead for the stock.",zacks.com,https://www.zacks.com/stock/news/2454560/johnson-johnson-jnj-is-attracting-investor-attention-here-is-what-you-should-know?cid=CS-STOCKNEWSAPI-FT-tale_of_the_tape|most_searched_stocks-2454560,https://images.financialmodelingprep.com/news/johnson-johnson-jnj-is-attracting-investor-attention-here-is-20250424.jpg
JNJ,2025-04-15,2025-04-01,2025-04-29,JNJ,,2025-04-24 08:34:00,2025-04-24T08:34:00-04:00,2025-04-24,3 Dividend Kings That Have Raised Their Payouts in 2025,"If you want to collect a lot of dividend income, it's important to focus on more than just a stock's current yield. Stocks that consistently grow their payouts over the years can be far more valuable investments to hang on to because that can ensure your dividend income is rising, possibly at a higher rate than inflation.",fool.com,https://www.fool.com/investing/2025/04/24/3-dividend-kings-that-have-raised-their-payouts-in/,https://images.financialmodelingprep.com/news/3-dividend-kings-that-have-raised-their-payouts-in-20250424.jpg
JNJ,2025-04-15,2025-04-01,2025-04-29,JNJ,,2025-04-24 07:46:40,2025-04-24T07:46:40-04:00,2025-04-24,Johnson & Johnson Just Proved The Bears Wrong Again,"Johnson & Johnson has started 2025 better than I expected, even with the long-running talc saga. It beat the consensus estimates again by a wide margin, thanks to its leading positions in the oncology and immunology market. So, sales of Tremfya amounted to $956 million, and Darzalex reached $3.24 billion in the first quarter of 2025, an increase of 18.3% and 20.2% year-on-year, respectively.",seekingalpha.com,https://seekingalpha.com/article/4777511-johnson-and-johnson-just-proved-the-bears-wrong-again,https://images.financialmodelingprep.com/news/johnson-johnson-just-proved-the-bears-wrong-again-20250424.jpg
JNJ,2025-04-15,2025-04-01,2025-04-29,JNJ,,2025-04-24 03:51:00,2025-04-24T03:51:00-04:00,2025-04-24,In the Wake of the Trump Tariff Crash: 2 Unparalleled Dividend Stocks to Buy at a Discount Right Now,"Every so often, Wall Street offers a reminder to investors that, despite popular belief, stocks don't rise in a straight line. Although the annualized return of stocks over the last century trumps all other asset classes, corrections, bear markets, and even crashes are normal, healthy, and inevitable.",fool.com,https://www.fool.com/investing/2025/04/24/trump-tariff-crash-2-dividend-stocks-buy-discount/,https://images.financialmodelingprep.com/news/in-the-wake-of-the-trump-tariff-crash-2-20250424.jpg
JNJ,2025-04-15,2025-04-01,2025-04-29,JNJ,,2025-04-25 14:16:00,2025-04-25T14:16:00-04:00,2025-04-25,Dividend Kings Face-Off: Johnson & Johnson (JNJ) Vs. Procter & Gamble (PG),"If you are someone who thinks investments should generate regular income, it is important to watch out for dividend stocks.",247wallst.com,https://247wallst.com/investing/2025/04/25/dividend-kings-face-off-johnson-johnson-jnj-vs-procter-gamble-pg/,https://images.financialmodelingprep.com/news/dividend-kings-faceoff-johnson-johnson-jnj-vs-procter-gamble-20250425.jpg
JNJ,2025-04-15,2025-04-01,2025-04-29,JNJ,,2025-04-25 03:00:00,2025-04-25T03:00:00-04:00,2025-04-25,"TREMFYA® (guselkumab) receives European Commission approval for adults with moderately to severely active ulcerative colitis, strengthening Johnson & Johnson's leadership in inflammatory bowel disease","The first a approved fully-human, dual-acting interleukin-23 (IL-23) inhibitor in moderately to severely active ulcerative colitis, 1 , 2 , 3 , 4 , 5 guselkumab showed statistically higher rates of endoscopic normalisation b at Week 44 compared with placebo. 2, 6 , 7 , 8 , 9",globenewswire.com,https://www.globenewswire.com/news-release/2025/04/25/3068097/0/en/TREMFYA-guselkumab-receives-European-Commission-approval-for-adults-with-moderately-to-severely-active-ulcerative-colitis-strengthening-Johnson-Johnson-s-leadership-in-inflammatory.html,https://images.financialmodelingprep.com/news/tremfya-guselkumab-receives-european-commission-approval-for-adults-with-20250425.jpg
JNJ,2025-04-15,2025-04-01,2025-04-29,JNJ,,2025-04-26 14:00:00,2025-04-26T14:00:00-04:00,2025-04-26,"Johnson & Johnson's TAR-200 monotherapy achieves high disease-free survival of more than 80 percent in BCG-unresponsive, high-risk papillary NMIBC","First results from SunRISe-1 (Cohort 4) show strong disease-free survival rates across high-grade papillary tumours, demonstrating the potential for bladder preservation with 94 percent of patients avoiding radical cystectomy 1",globenewswire.com,https://www.globenewswire.com/news-release/2025/04/26/3068774/0/en/Johnson-Johnson-s-TAR-200-monotherapy-achieves-high-disease-free-survival-of-more-than-80-percent-in-BCG-unresponsive-high-risk-papillary-NMIBC.html,https://images.financialmodelingprep.com/news/johnson-johnsons-tar200-monotherapy-achieves-high-diseasefree-survival-of-20250426.jpg
JNJ,2025-04-15,2025-04-01,2025-04-29,JNJ,,2025-04-26 14:00:00,2025-04-26T14:00:00-04:00,2025-04-26,"Johnson & Johnson's TAR-200 monotherapy achieves high disease-free survival of more than 80 percent in BCG-unresponsive, high-risk papillary NMIBC","First results from SunRISe-1 (Cohort 4) show strong disease-free survival rates across high-grade papillary tumors, demonstrating the potential for bladder preservation with 94 percent of patients avoiding radical cystectomy 95 percent progression-free survival rate at 9-months signals the promise of TAR-200 in this high-risk patient population LAS VEGAS , April 26, 2025 /PRNewswire/ -- Johnson & Johnson (NYSE: JNJ) today announced first results from Cohort 4 of the Phase 2b SunRISe-1 study evaluating TAR-200—an intravesical gemcitabine releasing system—for patients with certain types of bladder cancer. These first results show the promise of TAR-200 in this patient population with more than an 80 percent disease-free survival (DFS) rate without the need for reinduction and 94 percent of patients able to preserve their bladder.",prnewswire.com,https://www.prnewswire.com/news-releases/johnson--johnsons-tar-200-monotherapy-achieves-high-disease-free-survival-of-more-than-80-percent-in-bcg-unresponsive-high-risk-papillary-nmibc-302438971.html,https://images.financialmodelingprep.com/news/johnson-johnsons-tar200-monotherapy-achieves-high-diseasefree-survival-of-more-20250426.jpg
JNJ,2025-04-15,2025-04-01,2025-04-29,JNJ,,2025-04-26 13:50:00,2025-04-26T13:50:00-04:00,2025-04-26,Johnson & Johnson's TAR-200 monotherapy demonstrates highest complete response rate reported to date with sustained clinical benefits in patients with certain types of bladder cancer,Phase 2b SunRISe-1 study shows more than 82 percent of patients achieved complete response (CR) with more than half of responders remaining cancer-free at one year after CR1,globenewswire.com,https://www.globenewswire.com/news-release/2025/04/26/3068773/0/en/Johnson-Johnson-s-TAR-200-monotherapy-demonstrates-highest-complete-response-rate-reported-to-date-with-sustained-clinical-benefits-in-patients-with-certain-types-of-bladder-cancer.html,https://images.financialmodelingprep.com/news/johnson-johnsons-tar200-monotherapy-demonstrates-highest-complete-response-rate-20250426.jpg
JNJ,2025-04-15,2025-04-01,2025-04-29,JNJ,,2025-04-26 13:50:00,2025-04-26T13:50:00-04:00,2025-04-26,Johnson & Johnson's TAR-200 monotherapy demonstrates highest complete response rate with sustained clinical benefits in patients with certain types of bladder cancer,"Phase 2b SunRISe-1 study shows more than 82 percent of patients achieved complete response (CR) with more than half of responders remaining cancer-free at one year after CR Results reinforce potential of TAR-200 to transform outcomes for certain types of BCG-unresponsive, high-risk non-muscle invasive bladder cancer LAS VEGAS , April 26, 2025 /PRNewswire/ -- Johnson & Johnson (NYSE: JNJ) today announced new data from Cohort 2 of the pivotal Phase 2b SunRISe-1 study evaluating TAR-200—an intravesical gemcitabine releasing system—for patients with certain types of bladder cancer. The findings demonstrate the highest complete response rate without reinduction with more than half of responders remaining cancer-free for at least 12 months.",prnewswire.com,https://www.prnewswire.com/news-releases/johnson--johnsons-tar-200-monotherapy-demonstrates-highest-complete-response-rate-with-sustained-clinical-benefits-in-patients-with-certain-types-of-bladder-cancer-302438939.html,https://images.financialmodelingprep.com/news/johnson-johnsons-tar200-monotherapy-demonstrates-highest-complete-response-rate-with-20250426.jpg
JNJ,2025-04-15,2025-04-01,2025-04-29,JNJ,,2025-04-26 10:15:00,2025-04-26T10:15:00-04:00,2025-04-26,These 2 Top Dividend Stocks Are Making Moves to Avoid the Impact of Tariffs: Are They Buys?,"President Donald Trump's macroeconomic policies are taking center stage on Wall Street. The 47th U.S. president has decided to implement aggressive tariffs on imported goods from most countries, although he recently paused these plans for 90 days.",fool.com,https://www.fool.com/investing/2025/04/26/these-2-top-dividend-stocks-making-moves-to-avoid-/,https://images.financialmodelingprep.com/news/these-2-top-dividend-stocks-are-making-moves-to-20250426.jpg
JNJ,2025-04-15,2025-04-01,2025-04-29,JNJ,,2025-04-28 19:16:07,2025-04-28T19:16:07-04:00,2025-04-28,"Trump to tout US investments from Nvidia, J&J, Hyundai, Toyota","CEOs and other executives from Nvidia , Johnson & Johnson , Toyota Motor , Eli Lilly and SoftBank Group are among the more than two-dozen senior business leaders slated to visit the White House on Wednesday as part of an event highlighting U.S. investments, officials told Reuters.",reuters.com,https://www.reuters.com/business/autos-transportation/trump-tout-us-investments-nvidia-jj-hyundai-toyota-2025-04-28/,https://images.financialmodelingprep.com/news/trump-to-tout-us-investments-from-nvidia-jj-hyundai-20250428.jpg
JNJ,2025-04-15,2025-04-01,2025-04-29,JNJ,,2025-04-28 18:00:00,2025-04-28T18:00:00-04:00,2025-04-28,My 10 Must-Own Dividend Stocks For Your Retirement Portfolio (One Yields 9.65%),"I present 10 must-own dividend stocks for your retirement portfolio to help you blend dividend income, growth and capital appreciation, designed to anchor a well-diversified dividend portfolio. Allianz, BlackRock, Microsoft and Visa offer strong potential for dividend growth and capital appreciation when investing over the long term. Chevron, Realty Income, and Ares Capital provide attractive Dividend Yields, aligning well with income-focused investment strategies for long term retirement planning.",seekingalpha.com,https://seekingalpha.com/article/4778061-my-10-must-own-dividend-stocks-for-your-retirement-portfolio-one-yields-9-65-percent-,https://images.financialmodelingprep.com/news/my-10-mustown-dividend-stocks-for-your-retirement-portfolio-20250428.jpg
JNJ,2025-04-15,2025-04-01,2025-04-29,JNJ,,2025-04-28 16:22:00,2025-04-28T16:22:00-04:00,2025-04-28,Johnson & Johnson to Participate in the Bernstein's 41st Annual Strategic Decisions Conference,"NEW BRUNSWICK, N.J.--(BUSINESS WIRE)--Johnson & Johnson (NYSE: JNJ) will present at the Bernstein's 41st Annual Strategic Decisions Conference on Wednesday, May 28th, 2025. Management will participate in a Fireside Chat at 10:00 a.m. Eastern Time. A live audio webcast of the presentation will be accessible through Johnson & Johnson's Investor Relations website at www.investor.jnj.com. An archived edition of the session will be available later that day. The audio webcast replay will be a.",businesswire.com,https://www.businesswire.com/news/home/20250428942864/en/Johnson-Johnson-to-Participate-in-the-Bernstein%E2%80%99s-41st-Annual-Strategic-Decisions-Conference/,https://images.financialmodelingprep.com/news/johnson-johnson-to-participate-in-the-bernsteins-41st-annual-20250428.jpg
JNJ,2025-04-15,2025-04-01,2025-04-29,JNJ,,2025-04-28 09:45:05,2025-04-28T09:45:05-04:00,2025-04-28,3 Industry Behemoths Are Rewarding Investors With Dividend Bumps,"In a market where investors are increasingly seeking stability and reliable returns, several industry giants have stepped up with significant dividend increases. Johnson & Johnson NYSE: JNJ, Costco Wholesale NASDAQ: COST, and NASDAQ NASDAQ: NDAQ have each announced meaningful hikes to their quarterly payouts, reinforcing their commitment to shareholder value even amid broader market volatility.",marketbeat.com,https://www.marketbeat.com/stock-ideas/3-industry-behemoths-are-rewarding-investors-with-dividend-bumps/,https://images.financialmodelingprep.com/news/3-industry-behemoths-are-rewarding-investors-with-dividend-bumps-20250428.jpg
JNJ,2025-04-15,2025-04-01,2025-04-29,JNJ,,2025-04-28 07:28:23,2025-04-28T07:28:23-04:00,2025-04-28,3 Top Big Pharma Stocks Investing Over $100 Billion in the U.S.,Amid recession worries and tumbling markets; President Trump's tariffs are still helping the U.S. economy achieve key wins. Many huge corporations have announced plans to invest billions in U.S. manufacturing.,marketbeat.com,https://www.marketbeat.com/originals/3-top-big-pharma-stocks-investing-over-100-billion-in-the-us/,https://images.financialmodelingprep.com/news/3-top-big-pharma-stocks-investing-over-100-billion-20250428.jpg
